Mental Health & Substance Abuse Services, Dept. of - As enacted, enacts the "HOPE Treatment Act." - Amends TCA Title 9; Title 33; Title 53; Title 63 and Title 68.

HB 2075, the "Helping Open Pathways to Effective (HOPE) Treatment Act," proposes to establish a framework for Tennessee to conduct clinical trials of ibogaine - a Schedule I drug with potential for treating opioid use disorder, PTSD, depression, and other conditions - by amending state laws. The bill creates a process for "cohorts" (groups including drug developers, research institutions, and hospitals) to submit detailed proposals to the Department of Mental Health for FDA-approved trials, requiring specific plans for participant recruitment, safety protocols, and breakthrough therapy designation. It directly affects Tennessee's mental health department, healthcare institutions, and pharmaceutical developers seeking to advance ibogaine research. The bill does not fund trials but enables state participation in federal clinical pathways, aiming to accelerate FDA approval for ibogaine as a medical treatment.